Share this video  

ASCO GI 2023 | Who benefits from immunotherapy in patients with advanced ESCC?

Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, comments on the role of immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (ESCC). Patients with PD-L1-high ESCC benefit the most from immunotherapy, whereas a metanalysis of Phase III trials concluded that immunotherapy is not as efficacious in PD-L1-low patients, highlighting the need for PD-L1 testing. Strategies to enhance efficacy include combination regimens with existing immunotherapies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.